Epigral Ltd
Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.
In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.
- Market Cap ₹ 8,440 Cr.
- Current Price ₹ 1,956
- High / Low ₹ 2,408 / 1,502
- Stock P/E 19.6
- Book Value ₹ 441
- Dividend Yield 0.31 %
- ROCE 24.9 %
- ROE 22.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 24.8%
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|
394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,505 | |
245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,808 | |
Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 711 | 698 |
OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% | 28% |
2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 15 | 21 | |
Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 53 | 62 |
Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 133 | 141 |
Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 540 | 516 |
Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | 34% | |
67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 357 | 431 | |
EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 82.68 | 100.64 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 11% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | 18% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 12% |
TTM: | 72% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
1 Year: | 7% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 25% |
Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 43 |
Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,860 |
190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 593 | |
55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 655 | |
Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 |
364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | |
CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 64 |
Investments | 0 | 29 | 71 | 0 | 0 | 0 | 0 | 21 | 21 | 97 |
106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 752 | |
Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
165 | 229 | 284 | 626 | 398 | 441 | |||||
-363 | -197 | -455 | -437 | -401 | -262 | |||||
69 | -32 | 195 | -200 | -8 | -164 | |||||
Net Cash Flow | -129 | 1 | 24 | -11 | -11 | 15 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 | 33 |
Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 | 105 |
Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 63 | 50 |
Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 61 | 88 |
Working Capital Days | 43 | 40 | 19 | -27 | -76 | -92 | -26 | -41 | -54 | 26 |
ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1d - Q1FY26 revenue ₹615 Cr, PAT ₹160 Cr; capex on CPVC, Epichlorohydrin expansions on schedule.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
1d - Investor Presentation on Un-Audited Financial Results Q1 FY2026.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, 2Nd August, 2025 And Submission Of Un-Audited Financial Results (Standalone & Consolidated) For The First Quarter Ended On 30Th June, 2025.
1d - Q1 FY26 results: Rs. 160.41 Cr PAT; approved Rs. 400 Cr debt fund raise; invested in 19.8 MW renewable project.
-
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30.06.2025.
1d - Q1 FY26 results: Rs.160.41 Cr PAT; approved Rs.400 Cr debt fund raise; invested Rs.21.38 Cr in renewable energy.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30 Jul - Conference call on 4 Aug 2025 to discuss Epigral's Q1 FY26 financial results.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
Apr 2024TranscriptPPT
-
Apr 2024Transcript PPT
-
Apr 2024TranscriptNotesPPT REC
-
Apr 2024TranscriptNotesPPT
-
Jan 2024TranscriptPPT
-
Jan 2024Transcript PPT REC
-
Jan 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Apr 2023Transcript PPT REC
-
Jan 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022TranscriptNotesPPT
-
Apr 2022Transcript PPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]